Wi-Fi, Smartphones, and Surveillance: The New Face of Schizophrenia Delusions
December 18, 2025
Brand Name :
N/A
Synonyms :
asnuciclib, CDKI-73, LS-007
Class :
Antineoplastic agents, CDK-9 inhibitors
Dosage forms and strength
It is an investigational drug studied for its effectiveness to treat primary leukemia
Pediatric
Not determined
Actions and spectrum:
Asnuciclib is a CDK9 inhibitor. It inhibits the phosphorylation of RNAPII. It is an innovative pharmacological inhibitor of innate immune secretion and Rab11 cargo delivery.
None
Black box warning
None
Contraindication/Caution:
None
Pregnancy Warnings:
Pregnancy category: N/A
Lactation: Excretion of the drug into the human breast milk is unknown
Pregnancy categories:
Pharmacology:
Asnuciclib is a potential inhibitor of CDK9. It is a novel pharmacological inhibitor of Rab11 cargo delivery and innate immune secretion.
Pharmacodynamics:
Asnuciclib exhibits an affinity for primary cells of leukemia and is highly cytotoxic to these cells which are derived from chronic lymphatic leukemia patients (CLL).
Pharmacokinetics:
Limited information is available on ADME.
Administration:
The route of administration is not fully known.
Patient information leaflet
Generic Name: asnuciclib
Why do we use asnuciclib?
Asnuciclib is an antineoplastic agent thus its efficacy has been studied in treatment of primary leukemia.